Table A7.
Occurrence of respiratory syncytial virus (RSV) A and RSV B infections in cases of acute respiratory infection (ARI) and lower respiratory tract disease with 3 or more signs/symptoms (LRTD 3+) among subjects having received a placebo during RCT in the primary season (1st) or during the follow-up (FU).
| Vaccine | Placebo (N.) | RSV A (n./N., %) |
RSV B (n./N., %) |
Ratio RSV A/B | ||||
|---|---|---|---|---|---|---|---|---|
| Season | ARI | LRTD 3+ | ARI | LRTD 3+ | ARI | LRTD 3+ | ||
| mRNA-1345 | 1st | 17,516 | 51 (0.29) | 10 (0.06) | 31 (0.18) | 7 (0.04) | 1.645 | 1.429 |
| FU | 18,045 | 106 (0.59) | 30 (0.17) | 80 (0.44) | 22 (0.12) | 1.325 | 1.364 | |
| RSVpreF | 1st | 17,069 | 12 (0.07) | 3 (0.02) | 45 (0.26) | 10 (0.06) | 0.267 | 0.300 |
| FU | 9992 | 62 (0.62) | 10 (0.10) | 25 (0.25) | 3 (0.03) | 2.480 | 3.333 | |
| RSVPreF3 | 1st | 12,494 | 32 (0.26) | 13 (0.10) | 61 (0.49) | 26 (0.21) | 0.525 | 0.500 |
| FU | 4991 | - | 34 (0.68) | - | 57 (1.14) | - | 0.596 | |